Navigation Links
Sunflowers Could Hold the Key to New Class of AIDS Drugs

Scientists at the University of Bonn in Germany have come up with what could be a potential AIDS drug. They have found that a substance present in sunflowers prevents // the AIDS virus from replicating in cell cultures. It is not yet known if this would also apply to the actual disease.

The substance called as 'DCQA' has been the sole hope of producing a new class of AIDS drugs. But this is available in very minute quantities and naturally is pretty costly. The researchers from Bonn worked in collaboration with the Caesar research centre to make this substance available at a fraction of the earlier costs. The attempt to find the substance in sunflowers started with a mould called sclerotinia sclerotiorum. It was found that some varieties of sunflower were resistant to a disease called "white stem rot' that destroys the crops. Agricultural engineer Claudio Cerboncini proceeded to isolate the substance that confers protection on the sunflowers that are resistant to this fungal disease. The substance was dicaffeoyl quinic acid, or DCQA. "Dicaffeoyl quinic acid can prevent the HI virus from reproducing, at least in cell cultures," said Claudio Cerboncini.

"It is one of the few substances known today which inhibit viral integrase - this is an enzyme which is essential if the pathogen is to reproduce." Preliminary clinical tests have now borne out the hope that DCQA could herald in a new class of AIDS drugs. Dr. Esther Vogt of the Immunological Out-Patient Service of Bonn University Clinic, said, "We need these substances to expand our arsenal of effective weapons against the disease. It remains to be seen, however, whether they will prove to be as effective in clinical practice as they seem to be at present." The University of Bonn researchers have teamed up with Jülich Research Centre to see if they can manufacture this substance on a large scale.

Contact
Dr. Ralf Theisen
r.theisen@uni-bonn.de
University of Bonn
www.un i-bonn.de

'"/>




Related medicine news :

1. Oleic-acid-rich Sunflowers Give Trans-fat Alternative - Study
2. Lean Protein Could Be Key to Obesity Drugs
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Nasal Spray Could Take Drugs Directly to Brain
5. Oxygen Usage During Exercise Could Indicate Heart Problems
6. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
7. Anger Could Be Linked To Weight Gain
8. A Seizure Late In Life Could be A Stroke Warning
9. New Findings Could Reduce The Extent Of Spinal Cord Injuries
10. Could There Be A Link Between Famine and Breast Cancer ?
11. Bone Marrow Cells Could Yield A New Lease of Life
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson who has ... Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , The sessions ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... As renowned, ... heard the dangers and downsides of patients who do not do their research and ... of cosmetic dermatology is in the midst of a renaissance and every other month ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly released study ... the reproducibility and accuracy of placing precordial electrodes with little cognitive effort and ... last 60 years, studies have shown that single electrode misplacement is one of ...
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who ... now take advantage of a cosmetic procedure known as Carbon Dioxide (C02) ... the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, skin ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... a Phase 2 clinical study of sotagliflozin, a dual ... with JDRF, the leading global organization funding type 1 ... 2 clinical trial, which randomized a total of 87 ... 400 mg dose of sotagliflozin compared to a placebo ...
(Date:12/5/2016)... -- Sharn Anesthesia Inc. announced today that it has been ... Salter Labs.  The company also received the 2015 Salter ... sales performance. Salter Labs is a leading ... the market gold standard ECO 2 sampling cannulas. ... Parker Flex-Tip® Endotracheal Tube, which is a leading patient ...
(Date:12/5/2016)... , the first HIPAA compliant software collaboration platform for patients, physicians ... Styku, a California -based software and ... real-time 3D body scanning and analysis. Together with its other strategic ... feel their health like never before. ... , , "Bringing ...
Breaking Medicine Technology: